{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:08:56Z","timestamp":1779275336425,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11845-025-04228-4","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:37:44Z","timestamp":1765870664000},"page":"895-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antipsychotic treatment patterns and predictors of polypharmacy in psychotic disorders: 20-year real-world data from a tertiary center"],"prefix":"10.1007","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-0888","authenticated-orcid":false,"given":"Ece","family":"Da\u011fdemir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-7634","authenticated-orcid":false,"given":"Hacer Akg\u00fcl","family":"Ceyhun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7706-6751","authenticated-orcid":false,"given":"Fatma Tuygar","family":"Okutucu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"7","key":"4228_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0020764020922276","volume":"66","author":"V Peritogiannis","year":"2020","unstructured":"Peritogiannis V, Gogou A, Samakouri M (2020) Very long-term outcome of psychotic disorders. Int J Soc Psychiatry 66(7):633\u2013641. https:\/\/doi.org\/10.1177\/0020764020922276","journal-title":"Int J Soc Psychiatry"},{"key":"4228_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. APA, Washington DC","edition":"5"},{"key":"4228_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ajp.06.013","volume":"35","author":"BL Tan","year":"2016","unstructured":"Tan BL, Lee SA, Lee J (2016) Social cognitive interventions for people with schizophrenia: a systematic review. Asian J Psychiatry 35:115\u2013131. https:\/\/doi.org\/10.1016\/j.ajp.06.013","journal-title":"Asian J Psychiatry"},{"issue":"9","key":"4228_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0706743717720197","volume":"62","author":"S Abidi","year":"2017","unstructured":"Abidi S, Mian I, Garcia-Ortega I et al (2017) Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth. Can J Psychiatry 62(9):635\u2013647. https:\/\/doi.org\/10.1177\/0706743717720197","journal-title":"Can J Psychiatry"},{"issue":"6","key":"4228_CR5","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/schbul\/sbt137","volume":"39","author":"S Farooq","year":"2013","unstructured":"Farooq S, Agid O, Foussias G et al (2013) Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull 39(6):1169\u201372. https:\/\/doi.org\/10.1093\/schbul\/sbt137","journal-title":"Schizophr Bull"},{"issue":"1","key":"4228_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","volume":"138","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J et al (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138(1):18\u201328. https:\/\/doi.org\/10.1016\/j.schres.2012.03.018","journal-title":"Schizophr Res"},{"issue":"11","key":"4228_CR7","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1111\/bcp.13369","volume":"83","author":"J Brett","year":"2017","unstructured":"Brett J, Daniels B, Karanges EA et al (2017) Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol 83(11):2581\u20138. https:\/\/doi.org\/10.1111\/bcp.13369","journal-title":"Br J Clin Pharmacol"},{"issue":"10202","key":"4228_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"4228_CR9","doi-asserted-by":"publisher","first-page":"13509","DOI":"10.1038\/s41598-021-92731-w","volume":"11","author":"V Gam\u00f3n","year":"2021","unstructured":"Gam\u00f3n V, Hurtado I, Salazar-Fraile J et al (2021) Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia. Sci Rep 11:13509. https:\/\/doi.org\/10.1038\/s41598-021-92731-w","journal-title":"Sci Rep"},{"key":"4228_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003150","author":"D Pickar","year":"2008","unstructured":"Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0003150","journal-title":"PLoS One"},{"key":"4228_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/pcn.12676","volume":"72","author":"SY Yang","year":"2018","unstructured":"Yang SY, Chen LY, Najoan E et al (2018) Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: fourth survey of research on Asian prescription patterns on antipsychotics. Psychiatry Clin Neurosci 72:572\u2013579. https:\/\/doi.org\/10.1111\/pcn.12676","journal-title":"Psychiatry Clin Neurosci"},{"key":"4228_CR12","volume-title":"Understanding Pharmacoepidemiology","author":"Y Yang","year":"2010","unstructured":"Yang Y, West-Strum D (2010) Understanding Pharmacoepidemiology. McGraw-Hill Medical, New York, NY"},{"key":"4228_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LJ, Anzia JM et al (2020) The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177:868\u2013872. https:\/\/doi.org\/10.1176\/appi.ajp.2020.177901","journal-title":"Am J Psychiatry"},{"key":"4228_CR14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00127-018-1534-x","volume":"53","author":"M Heslin","year":"2018","unstructured":"Heslin M, Khondoker M, Shetty H et al (2018) Inpatient use and area-level socio-environmental factors in people with psychosis. Soc Psychiatry Psychiatr Epidemiol 53:1133\u20131140. https:\/\/doi.org\/10.1007\/s00127-018-1534-x","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"4228_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.schres.2022.12.016","volume":"252","author":"SM Coury","year":"2023","unstructured":"Coury SM, Lombroso A, Avila-Quintero VJ et al (2023) Systematic review and meta-analysis: season of birth and schizophrenia risk. Schizophr Res 252:244\u2013252. https:\/\/doi.org\/10.1016\/j.schres.2022.12.016","journal-title":"Schizophr Res"},{"key":"4228_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/archpsyc.62.8.841","volume":"62","author":"TM Laursen","year":"2005","unstructured":"Laursen TM, Labouriau R, Licht RW et al (2005) Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Arch Gen Psychiatry 62:841. https:\/\/doi.org\/10.1001\/archpsyc.62.8.841","journal-title":"Arch Gen Psychiatry"},{"key":"4228_CR17","first-page":"328","volume":"56","author":"E Ertekin","year":"2021","unstructured":"Ertekin E, Ercis M, Aliyeva G et al (2021) Clinical profile of delusional disorder and its subtypes: a descriptive study from T\u00fcrkiye. Riv Psichiatr 56:328\u2013333","journal-title":"Riv Psichiatr"},{"issue":"2\u20133","key":"4228_CR18","first-page":"619","volume":"200","author":"NP Maric","year":"2012","unstructured":"Maric NP, Krabbendam L, Vollebergh W et al (2012) Symptom dimensions and duration of untreated psychosis in first-episode psychosis. Psychiatry Res 200(2\u20133):619\u2013623","journal-title":"Psychiatry Res"},{"key":"4228_CR19","doi-asserted-by":"crossref","unstructured":"Olivares JM, Sermon J, Hemels M et al (2013) Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Annals Gen Psychi, 1","DOI":"10.1186\/1744-859X-12-32"},{"issue":"4","key":"4228_CR20","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/eip.13046","volume":"15","author":"M Zhu","year":"2021","unstructured":"Zhu M, Ferrara M, Tan W et al (2021) Drug-na\u00efve first-episode schizophrenia spectrum disorders: Pharmacological treatment patterns in inpatient units in China. Early Interv Psychiatry 15(4):1010\u20131018","journal-title":"Early Interv Psychiatry"},{"key":"4228_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5505\/kpd.2020.42103","volume":"23","author":"Y \u015eafak","year":"2020","unstructured":"\u015eafak Y, Do\u011fan Bulut S, Karada\u011f H et al (2020) Evaluation of long acting, oral and combination antipsychotic treatments in patients with psychotic disorder (tur). J Clin Psychiatry 23:72\u201382. https:\/\/doi.org\/10.5505\/kpd.2020.42103","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"4228_CR22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bdi.12133","volume":"16","author":"GS Malhi","year":"2014","unstructured":"Malhi GS, Green M, Fagiolini A et al (2014) Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disord 16(5):436\u2013447","journal-title":"Bipolar Disord"},{"key":"4228_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/eip.13046","volume":"15","author":"M Zhu","year":"2021","unstructured":"Zhu M, Ferrara M, Tan W et al (2021) Drug-na\u00efve first\u2010episode schizophrenia spectrum disorders: pharmacological treatment practices in inpatient units in Hunan Province, China. Early Interv Psychiatry 15:1010\u20131018. https:\/\/doi.org\/10.1111\/eip.13046","journal-title":"Early Interv Psychiatry"},{"issue":"7","key":"4228_CR24","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/bcp.13945","volume":"85","author":"M H\u00f8jlund","year":"2019","unstructured":"H\u00f8jlund M, Potteg\u00e5rd A, Johnsen E et al (2019) Trends in utilization and dosing of antipsychotic drugs in Scandinavia: comparison of 2006 and 2016. Br J Clin Pharmacol 85(7):1598\u20131606","journal-title":"Br J Clin Pharmacol"},{"key":"4228_CR25","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s00213-017-4730-6","volume":"234","author":"J Grigg","year":"2017","unstructured":"Grigg J, Worsley R, Thew C et al (2017) Antipsychotic- induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology 234:3279\u20133297. https:\/\/doi.org\/10.1007\/s00213-017-4730-6","journal-title":"Psychopharmacology"},{"key":"4228_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/07067437211055413","volume":"67","author":"O Agid","year":"2022","unstructured":"Agid O, Remington G, Fung C et al (2022) Real- world utilization patterns of long-acting injectable antipsychotics in Canada: a retrospective study. Can J Psychiatry 67:226\u2013234. https:\/\/doi.org\/10.1177\/07067437211055413","journal-title":"Can J Psychiatry"},{"key":"4228_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/JCP.0000000000000876","volume":"38","author":"BA Gaudiano","year":"2018","unstructured":"Gaudiano BA, Guzman Holst C, Morena A et al (2018) Complex polypharmacy in patients with Schizophrenia-Spectrum disorders before a psychiatric hospitalization: prescribing patterns and associated clinical features. J Clin Psychopharmacol 38:180. https:\/\/doi.org\/10.1097\/JCP.0000000000000876","journal-title":"J Clin Psychopharmacol"},{"key":"4228_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00115-018-0507-3","volume":"90","author":"HJ Assion","year":"2019","unstructured":"Assion HJ, Schweppe A, Reinbold H et al (2019) Pharmacological treatment for schizoaffective disorder. Nervenarzt 90:1\u20138. https:\/\/doi.org\/10.1007\/s00115-018-0507-3","journal-title":"Nervenarzt"},{"key":"4228_CR29","doi-asserted-by":"publisher","unstructured":"Boden R, Lundgren M, Brandt L et al (2011) Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 2012; 69:715\u2013721 https:\/\/doi.org\/10.1001\/archgenpsychiatry.1870","DOI":"10.1001\/archgenpsychiatry.1870"},{"issue":"7","key":"4228_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M et al (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatr 74(7):686\u2013693","journal-title":"JAMA Psychiatr"},{"issue":"2","key":"4228_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll CU, Detraux J, De Lepeleire J et al (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14(2):119\u2013136","journal-title":"World Psychiatry"},{"key":"4228_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","volume":"69","author":"J Tiihonen","year":"2012","unstructured":"Tiihonen J, Suokas JT, Suvisaari JM et al (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69:476\u2013483. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.1532","journal-title":"Arch Gen Psychiatry"},{"key":"4228_CR33","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S282856","author":"B Kearns","year":"2021","unstructured":"Kearns B, Cooper K, Cantrell A, Thomas C (2021) Schizophrenia treatment with second-generation antipsychotics: a multi-country comparison of the costs of cardiovascular and metabolic adverse events and weight gain. Neuropsychiatr Dis Treat. https:\/\/doi.org\/10.2147\/NDT.S282856","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"12","key":"4228_CR34","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/17425255.2020.1821646","volume":"16","author":"JM Azorin","year":"2020","unstructured":"Azorin JM, Simon N (2020) Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opin Drug Metab Toxicol 16(12):1175\u20131186","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-04228-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04228-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:41:36Z","timestamp":1779273696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-04228-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4228"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-04228-4","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}